Evidence map›Paper›PMID 35042235›Full record

ArticleBlood advances2022

Patient-specific MDS-RS iPSCs define the mis-spliced transcript repertoire and chromatin landscape of SF3B1-mutant HSPCs.

Georgios Asimomitis, André G Deslauriers, Andriana G Kotini, Elsa Bernard, Davide Esposito, Malgorzata Olszewska, Nikolaos Spyrou, Juan Arango Ossa, Teresa Mortera-Blanco, Richard Koche and 8 more

Open access · goldAbstract read
In one paragraph

Article in Blood advances, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.5field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 17 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 5 institutions in 7 countries.

Georgios AsimomitisComputational Oncology Service, Department of Epidemiology & Biostatistics, and.ORCID 0000-0002-9479-5451
André G DeslauriersComputational Oncology Service, Department of Epidemiology & Biostatistics, and.ORCID 0000-0002-2854-5681
Andriana G KotiniDepartment of Oncological Sciences.ORCID 0000-0001-9148-6015
Elsa BernardComputational Oncology Service, Department of Epidemiology & Biostatistics, and.ORCID 0000-0002-2057-7187
Davide EspositoDepartment of Oncological Sciences.
Malgorzata OlszewskaDepartment of Oncological Sciences.
Nikolaos SpyrouDepartment of Oncological Sciences.ORCID 0000-0001-5274-1749
Juan Arango OssaComputational Oncology Service, Department of Epidemiology & Biostatistics, and.ORCID 0000-0003-1109-6178
Teresa Mortera-BlancoCenter for Hematology and Regenerative Medicine, Karolinska Institute, Department of Medicine, Karolinska University Hospital Huddinge, Stockholm, Sweden.
Richard KocheCenter for Epigenetics Research, Memorial Sloan-Kettering Cancer Center, New York, NY.
Yasuhito NannyaDepartment of Pathology and Tumor Biology, Kyoto University, Kyoto, Japan.
Luca MalcovatiUnit of Precisione Hematology Oncology, Istituto di Ricovero e Cura a Carattere Scientifico S. Matteo Hospital Foundation, Pavia, Italy; and.ORCID 0000-0002-1460-1611
Seishi OgawaDepartment of Pathology and Tumor Biology, Kyoto University, Kyoto, Japan.ORCID 0000-0002-7778-5374
Mario CazzolaDepartment of Molecular Medicine, University of Pavia, Pavia, Italy.
Stuart A AaronsonDepartment of Oncological Sciences.ORCID 0000-0002-4643-0474
Eva Hellström-LindbergCenter for Hematology and Regenerative Medicine, Karolinska Institute, Department of Medicine, Karolinska University Hospital Huddinge, Stockholm, Sweden.
Elli PapaemmanuilComputational Oncology Service, Department of Epidemiology & Biostatistics, and.
Eirini P PapapetrouDepartment of Oncological Sciences.ORCID 0000-0001-7002-417X
Cancer Institute (WIA) · INMemorial Sloan Kettering Cancer Center · USKarolinska University Hospital · SEKyoto University · JPUniversity of Pavia · IT

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
Dissecting splicing factor mutations in iPSCsR01HL137219 · NHLBI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI PAPAPETROU, EIRINI, YEO, EUGENE WEI-MING · 2017 to 2020
$3.2M
Identification of therapeutic targets for leukemia stem cells in AML-iPSC modelsR01CA225231 · NCI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI KHARAS, MICHAEL, PAPAPETROU, EIRINI · 2018 to 2022
$3.2M
NCI NIH HHS P30 CA008748NCI NIH HHS R01 CA225231NHLBI NIH HHS R01 HL137219
6 · The paper itself

Abstract

SF3B1K700E is the most frequent mutation in myelodysplastic syndrome (MDS), but the mechanisms by which it drives MDS pathogenesis remain unclear. We derived a panel of 18 genetically matched SF3B1K700E- and SF3B1WT-induced pluripotent stem cell (iPSC) lines from patients with MDS with ring sideroblasts (MDS-RS) harboring isolated SF3B1K700E mutations and performed RNA and ATAC sequencing in purified CD34+/CD45+ hematopoietic stem/progenitor cells (HSPCs) derived from them. We developed a novel computational framework integrating splicing with transcript usage and gene expression analyses and derived a SF3B1K700E splicing signature consisting of 59 splicing events linked to 34 genes, which associates with the SF3B1 mutational status of primary MDS patient cells. The chromatin landscape of SF3B1K700E HSPCs showed increased priming toward the megakaryocyte- erythroid lineage. Transcription factor motifs enriched in chromatin regions more accessible in SF3B1K700E cells included, unexpectedly, motifs of the TEA domain (TEAD) transcription factor family. TEAD expression and transcriptional activity were upregulated in SF3B1-mutant iPSC-HSPCs, in support of a Hippo pathway-independent role of TEAD as a potential novel transcriptional regulator of SF3B1K700E cells. This study provides a comprehensive characterization of the transcriptional and chromatin landscape of SF3B1K700E HSPCs and nominates novel mis-spliced genes and transcriptional programs with putative roles in MDS-RS disease biology.

Indexed as

Induced Pluripotent Stem CellsMyelodysplastic SyndromesChromatinHumansMutationPhosphoproteinsRNA Splicing FactorsTranscription FactorsChromatinPhosphoproteinsRNA Splicing FactorsSF3B1 protein, humanTranscription Factors

Identifiers

PMID35042235
PMCPMC9131920
OpenAlexW4205578722

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.